Proton Pump

ORLANDO — An increase in discontinuation of medications that could have a positive impact on kidney outcomes resulted from a medication-targeted AKI alert, according to a presenter at ASN Kidney Week.

Concomitant proton pump inhibitor plus ticagrelor monotherapy after PCI does not increase risk for all-cause death or an adverse CV event, in contrast with conventional post-PCI antiplatelet therapy, researchers reported.

Patients who took proton pump inhibitors (PPIs) before cardiac surgery may be at an elevated risk for developing AKI, according to data presented at ASN Kidney Week.